Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS. Tzelepis K, et al. Among authors: bates do. Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0. Nat Commun. 2018. PMID: 30568163 Free PMC article.
Pharmacology of Modulators of Alternative Splicing.
Bates DO, Morris JC, Oltean S, Donaldson LF. Bates DO, et al. Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239. Pharmacol Rev. 2017. PMID: 28034912 Free PMC article. Review.
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J, Toop HD, Redondo C, Babaei-Jadidi R, Chaikuad A, Wearmouth SF, Gibbons B, Allen C, Tallant C, Zhang J, Du C, Hancox JC, Hawtrey T, Da Rocha J, Griffith R, Knapp S, Bates DO, Morris JC. Batson J, et al. Among authors: bates do. ACS Chem Biol. 2017 Mar 17;12(3):825-832. doi: 10.1021/acschembio.6b01048. Epub 2017 Feb 6. ACS Chem Biol. 2017. PMID: 28135068 Free article.
Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK, Allen CL, Stewart E, Horton KL, Riu F, Batson J, Amoaku W, Morris JC, Arkill KP, Bates DO. Malhi NK, et al. Among authors: bates do. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1014-H1027. doi: 10.1152/ajpheart.00001.2022. Epub 2022 Mar 18. Am J Physiol Heart Circ Physiol. 2022. PMID: 35302878 Free PMC article.
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR. Amin EM, et al. Among authors: bates do. Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016. Cancer Cell. 2011. PMID: 22172722 Free PMC article.
Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Supradit K, et al. Among authors: bates do. Toxicol In Vitro. 2022 Aug;82:105385. doi: 10.1016/j.tiv.2022.105385. Epub 2022 May 11. Toxicol In Vitro. 2022. PMID: 35568131
201 results